Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels

Endocrine Research

Volumn 30, Issue 3, 2004, Pages 443-453

  Zietz, B ^a   Buechler, C ^a   Drobnik, W ^b   Herfarth, H ^a   Scholmerich J ^a   Schaffler A ^a,b  

^a Department of Internal Medicine I ^*  (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Diabetes; Fibrinogen; PAI 1; Polymorphism; Promoter

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA;

ADIPOCYTE; AGED; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL;

AGED; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); STATISTICS, NONPARAMETRIC;

EID: 7544248528     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-200035728     Document Type: Article

References (37)

1. Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115:776-780.
2. Meade TW, Ruddock B, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
3. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor-1 and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1988; 98:2241-2247.
4. Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Bjorkander I. Eriksson SV, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: results from the angina prognosis study in Stockholm. Circulation 1997; 95:2380-2386.
5. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9.
6. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89:6998-7002.
7. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-10745.
8. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92:1851-1855.
9. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74:1032-1034.
10. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74:842-847.
11. Matsubara Y, Murata M, Isshiki I, Watanabe R, Zama T, Watanabe G. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol 1999; 69:43-47.
12. Hoffstedt J, Andersson IL, Persson L, Isaksson B, Arner P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002; 45:584-587.
13. Leander K, Wiman B, Hallqvist J, Sten-Linder M, De Faire U. PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction. Thromb Haemost 2003; 89:1064-1071.
14. Yamada Y, Izawa H, Ichihara S, Takatsa F, Ishihara H, Hirayama H. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923.
15. Nagi DK, Mc Cormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 1997; 20:1304-1309.
16. Globocnik-Petrovic M, Halina M, Peterlin B, Petrovic D. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Opthalmologica 2003; 217:219-224.
17. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2:800-803.
18. Samad F, Yamamoto K, Loskutoff D. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Investig 1996; 97:37-46.
19. Samad F, Schneiderman J, Loskutoff D. Expression of fibrinolytic genes in tissues from human atherosclerotic aneurysms and from obese mice. Ann N Y Acad Sci 1997; 811:350-358.
20. Alessi MC, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis. Horm Metab Res 2000; 32:504-508.
21. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32:78-84.
22. Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84:4097-4105.
23. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue. Diabetes 1997; 46:860-867.
24. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93:106-110.
25. Kohner EM, Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe. Eur J Ophthal 1991; 1:45-54.
26. Gregor PD, Sawadogo M, Roeder RG. The adenovirus major late transcription factor USF is a member of the helix-loop-helix group of regulatory proteins and binds to DNA as a dimer. Genes Dev 1990; 4:1730-1740.
27. Shieh BH, Sparkes RS, Gaynor RB, Lusis AJ. Localization of the gene encoding upstream stimulatory factor (USF) to human chromosome Iq22-q23. Genomics 1993; 16:266-268.
28. Groenen PMA, Garcia E, Debeer P, Devriendt K, Fryns JP, Van de Ven WJM. Structure, sequence, and chromosome 19 localization of human USF-2 and its rearrangement in a patient with multicystic renal dysplasia. Genomics 1996; 38:141-148.
29. Henrion AA, Martinez A, Mattei MG, Kahn A, Raymondjean M. Structure, sequence, and chromosomal localization of the gene for USF-2 transcription factor in mouse. Genomics 1995; 25:36-43.
30. Samoylenko A, Roth U, Jungermann K, Kietzmann T. The upstream stimulatory factor-2a inhibits plasminogen activator inhibitor-1 gene expression by binding to a promoter element adjacent to the hypoxia-inducible factor-1 binding site. Blood 2001; 97:2657-2666.
31. Providence KM, White LA, Tang J, Gonclaves J, Staiano-Coico L, Higgins PJ. Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator type 1 gene. J Cell Sci 2002; 115:3767-3777.
32. Festa A, D'Agostino R Jr, Rich SS, Jeny NS, Tracy RP, Haffner SM. Promoter (4G/ 5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in Blacks, Hispanics, and non-Hispanics Whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003; 107:2422-2427.
33. Westendorp RGJ, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-563.
34. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14:54-59.
35. Meade TW, Ruddock B, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
36. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80:749-756.
37. Mansfield MW, Stickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994; 71:731-736.